Edition:
United States

Lonza Group AG (LONN.S)

LONN.S on Virt-X Level 1

325.40CHF
19 Oct 2018
Change (% chg)

CHF-3.30 (-1.00%)
Prev Close
CHF328.70
Open
CHF327.50
Day's High
CHF334.20
Day's Low
CHF324.00
Volume
304,053
Avg. Vol
294,456
52-wk High
CHF342.00
52-wk Low
CHF218.00

Chart for

About

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The Life Science Ingredients division comprises a... (more)

Overall

Beta: 1.07
Market Cap(Mil.): CHF23,897.02
Shares Outstanding(Mil.): 74.47
Dividend: 2.75
Yield (%): 0.86

Financials

  LONN.S Industry Sector
P/E (TTM): 26.88 119.85 32.14
EPS (TTM): 11.94 -- --
ROI: 9.33 1.96 12.83
ROE: 15.36 1.12 14.95

BRIEF-Lonza - Production In Nansha To Close For Maintenance

* WILL SHUT DOWN ITS PRODUCTION OF NIACINAMIDE (VITAMIN B3) IN NANSHA (CN) IN DECEMBER 2018 TO PERFORM ROUTINE MAINTENANCE AND PROCESS OPTIMIZATION Further company coverage: (Berlin Speed Desk)

9:08am EDT

BRIEF-Lonza Group Affirms 2022 Guidance at Capital Markets Day

* CAPITAL MARKETS DAY 2018 OUTLINES SUSTAINABLE GROWTH PLANS THROUGH FOCUS AND INVESTMENT

Sep 25 2018

BRIEF-Lonza Group AG Expands Its Distribution Relationship With Azelis Americas

* SAYS LONZA CONSUMER PRODUCT INGREDIENTS EXPANDS ITS DISTRIBUTION RELATIONSHIP WITH AZELIS AMERICAS

Jul 16 2018

UPDATE 1-Lonza confirms targets as gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

May 04 2018

Lonza confirms targets as Q1 gets off to good start

ZURICH, May 4 Swiss drug ingredients maker Lonza confirmed its guidance on Friday and said it had got off to a good start this year.

May 04 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

May 03 2018

Samsung BioLogics' shares slide again; unit's valuation jump questioned

SEOUL, May 3 Shares in South Korea's Samsung BioLogics Co Ltd fell 3.5 percent on Thursday, a day after losing almost $6 billion in market value as the contract biotech drugmaker was hit by a regulatory probe into its accounting rules.

May 03 2018

UPDATE 3-Accounting concerns wipe $6 bln off Samsung BioLogics market value

* Financial watchdog gives preliminary notice to co on measures

May 02 2018

Earnings vs. Estimates